The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Ltd. have identified compounds acting as interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction, interleukin-17A/A (IL17A/A) ...

Co. Ltd. has disclosed compounds acting as interleukin-17A/A homodimer and IL-17A/F heterodimer inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory diseases.

PARIS — Doses of interleukin (IL)-17 and IL-23 inhibitors were safely reduced in people with plaque psoriasis who had “very stable low disease activity”; it was reported during a late-breaking news ...

The hidradenitis suppurativa market is poised for strong growth, driven by increasing disease awareness, earlier diagnosis, and expanding treatment access. Advances in biologic and targeted therapies, ...

A Danish registry study finds no substantial differences in the 5-year risk for first cancers between three biologics in patients with psoriasis.

In addition to the spine or joints, it can cause diseases in various organs of the body such as the eyes, skin, and gastrointestinal tract, so it is not a simple musculoskeletal disease, but a ...

A young woman shares her emotional 15-year journey with hidradenitis suppurativa, chronic skin inflammation for which ...

The "atopic march" describes the age-related progression of allergic diseases, presenting as the sequential onset of atopic ...

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the ...

(MENAFN- Market Press Release) September 28, 2025 8:37 am - The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is projected to reach USD 6.52 billion in 2025, growing at an 11% CAGR through 2032.